TVTX Projected Dividend Yield
Travere Therapeutics Inc ( NASDAQ : TVTX )Travere Therapeutics, Inc. is a biopharmaceutical company. Co. is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). Co.'s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. 21 YEAR PERFORMANCE RESULTS |
TVTX Dividend History Detail TVTX Dividend News TVTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |